Intellia Therapeutics Inc. Stock Price (NTLA) | Barron's Apr 03, 2020 · View today's stock price, news and analysis for Intellia Therapeutics Inc. (NTLA). Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation Intellia Therapeutics (NASDAQ:NTLA) Stock Price Up 6% ... Apr 07, 2020 · Intellia Therapeutics Inc (NASDAQ:NTLA)’s share price rose 6% during trading on Monday . The company traded as high as $12.72 and last traded at $12.71, approximately 480,287 shares changed hands during trading. A decline of 35% from the average daily volume of 743,192 shares. The stock had previously closed at $11.99. NTLA has been the […] Intellia Therapeutics, Inc. (NTLA) Stock Analysis & News ... Get breaking news and analysis on Intellia Therapeutics, Inc. (NTLA) stock, price quote and chart, trading and investing tools. Intellia Therapeutics Inc., NTLA Quick Chart - (NAS) NTLA ...
Intellia is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic. Our company’s unique strengths include our modular lipid nanoparticle delivery system and our determined focus on product development. Intellia Therapeutics Is A Buy (NASDAQ:NTLA) | Seeking Alpha Oct 13, 2016 · Shares of Intellia Therapeutics, one of the two publicly traded CRISPR/Cas9 gene editing companies, are trading at 52-week lows. We consider the current stock price … Intellia Therapeutics Inc. Stock Price (NTLA) | Barron's
Find the latest Intellia Therapeutics, Inc. (NTLA) stock quote, history, news and other vital information to help you with your stock trading and investing. Real time Intellia Therapeutics (NTLA) stock price quote, stock graph, news & analysis. 5 Jan 2020 Is Intellia Therapeutics Stock a Buy? Its CRISPR technology has the potential to cure certain genetic diseases, but investors who buy in now will NTLA | Complete Intellia Therapeutics Inc. stock news by MarketWatch. View real -time stock prices and stock quotes for a full financial overview. Stock analysis for Intellia Therapeutics Inc (NTLA:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company Intellia Therapeutics, Inc. Common Stock (NTLA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class.
the closing of its initial public offering of 6,900,000 shares of its common stock at an initial public offering price of $18.00 per share, which includes the exercise Based on 4 analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. The average price target is $31.83 with a high forecast of Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. NTLA, Intellia Therapeutics - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines. On eToro, you can buy $NTLA or other stocks and pay ZERO commission! Follow Intellia Therapeutics Inc share price and get more information. Terms apply.